App-Quantinova.ai

A single centre experience with azacitidine for MDS, AML and CMML in relation to cytogenetic risk and performance status. Our results suggest azacitidine use in the real world does not replicate AZA‐001 overall survival rates and has poorer outcomes

C. Page - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Myelodysplastic Syndrome

Vidaza

CD47 but Not Calreticulin Is over Expressed in Patients with Myeloproliferative Neoplasms

K. Boasman - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Myeloid neoplasms

Hydroxyurea

Cost‐effectiveness of gemtuzumab ozogamicin in combination with standard of care chemotherapy (daunorubicin and cytarabine) for first‐line treatment of acute myeloid leukaemia

R. Mokgokong - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

daunorubicin + cytarabine

Antithrombin III Replacement in patients with Acute Lymphoblastic Leukaemia undergoing L‐asparaginase based chemotherapy regimens

L. Attwell - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Thrombocytopenia

Asparaginase

Establishing a novel in vitro 3D co‐culture system to model and therapeutically target leukaemia‐bone marrow microenvironment interactions in Acute Myeloid Leukaemia

M. Williams - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

Immunol

Differential response to Src inhibition across AML cell lines gives insight on potential patient stratification for therapy

A. Gonzlez-Snchez - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

saracatinib

Characterising the Expression of the Stress Responsive Genes SAFB1 and SAFB2 in Childhood ALL

M. Allahyani - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Urology

Colorectal Cancer

celastrol

Interrogating gender influence on the prognosis and the overall survival of acute myeloid leukaemia (AML)

A.A. Sayed - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

N/A

Survival Outcomes of Elderly Acute Myeloid Leukaemia (AML) Patients Treated in a British District General Hospital

C. Agbuduwe - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute promyelocytic leukemia

Vidaza

Retrospective service evaluation of haematopoietic cell transplant outcomes of adult acute myeloid leukaemia patients with intermediate‐risk and adverse‐risk genetics transplanted in first complete remission at St. James's University Hospital

S. Portela - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

N/A

Assessing the needs for support in MDS patients

S. Wintrich - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Hematology-oncology disease

N/A

Myeloma UK Educational Resources: An Evaluation of the Myeloma Nurse Learning Programme

A. Capper - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

A Survey Of Haematology Education Amongst Senior Medical Students And Junior Doctors

O. Ahmad - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

A Qualitative Study to Evaluate Blood Film Morphology Teaching for Biomedical Scientists Led by Haematology Registrars

C.S. Booth - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Evaluation of the introduction of Physician Associates in the Haematology Department at Guy's and St. Thomas’ Hospitals Foundation NHS Trust

D. Sealy - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

‘The Silence Pact’: a qualitative study of cultural differences in breaking bad news

S. Holmes - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Reducing Inappropriate Blood Testing in Haematology Inpatients: A Multi‐Centre Quality Improvement Project

A. Fisher - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

CIP2A alters energy metabolism in CML cells, thus contributing to TKI resistance

J.A. Austin - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Tuberculosis

N/A

The UK Myeloproliferative Neoplasm Registry for Myelofibrosis (UK‐MPN‐MF registry)

N.M. Butt - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Myelofibrosis with myeloid metaplasia

N/A

BCL‐XL ‐ a biomarker to predict chronic myeloid leukaemia patients at risk of molecular relapse when TKI treatment is discontinued

C. Lucas - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

Imatinib

Filters

45280 Abstracts